Serum malondialdehyde: Possible use for the clinical management of chronic hepatitis C patients

Free Radical Biology and Medicine

Volumn 25, Issue 9, 1998, Pages 993-997

  Romero, María J ^b   Bosch Morell, Francisco ^b   Romero, Belén ^b   Rodrigo, José M ^a   Serra, Miguel A ^a   Romero, Francisco J ^b  

^a UNIVERSITY OF VALENCIA   (Spain)

^b NONE

Author keywords

Free radical; Hepatitis C virus; Interferon; Lipid peroxidation; Oxidative stress

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; LIPID; MALONALDEHYDE;

ARTICLE; ASTHENIA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HEADACHE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; HUMAN; LIPID PEROXIDATION; LIVER BIOPSY; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALONDIALDEHYDE; MIDDLE AGED;

HEPATITIS C VIRUS; RNA VIRUSES;

EID: 0032401621     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(98)00118-X     Document Type: Article

References (27)

1. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radical Biol. Med. 11:1991;81-128.
2. Suematsu T., Kamada T., Abe H., Kikuchi S., Yagi K. Serum lipid peroxide level in patients suffering from liver diseases. Clin. Chim. Acta. 79:1977;267-270.
3. Suematsu T., Matsumura T., Sato N. Lipid peroxidation in alcoholic liver disease in humans. Alcohol Clin. Exp. Res. 5:1981;427-430.
4. Yagi K. Lipid peroxides and human diseases. Chem. Phys. Lipids. 45:1987;337-351.
5. Higueras V., Raya A., Rodrigo J.M., Serra M.A., Romá J., Romero F.J. Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Radical Biol. Med. 15:1994;131-133.
6. Alter H.J., Purcell R.H., Holland P.V., Feinstone S.M., Morrow A.G., Moritsugu Y. Clinical and serological analysis of transfusion-associated hepatitis. Lancet. ii:1975;838-841.
7. Harrison T.R. Chronic hepatitis. Harrison's principles of internal medicine. 1994;1478-1483 McGraw-Hill, New York.
8. Tsai S.L., Liaw Y.F., Chen M.H., Huang C.Y., Kuo G.C. Detection of type 2-like T-helper cells in hepatitis C virus infection implications for hepatitis C virus chronicity . Hepatology. 25:1997;449-458.
9. Stuyver L., Fretz C., Esquivel C., Boudifa A., Jaulmes D., Azar N., Lunel F., Leroux-Roels G., Maertens G., Fournel J.J. Hepatitis C virus (HCV) genotype analysis in apparently healthy anti-HCV-positive Parisian blood donors. Transfusion. 36:1996;552-558.
10. Garcia-Fulgueiras A., Tormo M.J., Rodriguez T., Perez-Flores D., Chirlaque D., Navarro C. Prevalence of hepatitis B and C markers in the south-east of Spain an unlinked community-based serosurvey of 2203 adults . Scand. J. Infect. Dis. 28:1996;17-20.
11. Soetjipto, Handajani R., Lusida M.I., Darmadi S., Adi P., Soemarto, Ishido S., Katayama Y., Hotta H. Differential prevalence of hepatitis C virus subtypes in healthy blood donors, patients on maintenance hemodialysis, and patients with hepatocellular carcinoma in Surabaya, Indonesia. J. Clin. Microbiol. 34:1996;2875-2880.
12. Alter H.J. Clinical, virological and epidemiological basis for the treatment of chronic non-A, non-B hepatitis. J. Hepatol. 11:1990;S19-S25.
13. Seymour C. Asymptomatic infection with hepatitis C virus. Br. Med. J. 308:1994;670-671.
14. Berger A., vonDepka-Prondzinski M., Doerr H.W., Rabenau H., Weber B. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J. Med. Virol. 48:1996;339-343.
15. Iuliano R., Pizzigallo A.M., Alecci A., Barsanti L., Trovato R., Forastieri G., Lico S., Palmieri C., Brizzi M., Marino N., Mecocci L., Mazzotta F., Ceccherini-Nelli L. Quantitation of HCV viremia by branched DNA signal amplification in patients treated with alpha-interferon - A longitudinal study. Infection. 24:1996;292-296.
16. Quiroga J.A., Bosch O., Gonzalez R., Marriott E., Castillo I., Bartolome J., Carreño V. Immunoglobulin M antibody to hepatitis C virus during interferon therapy for chronic hepatitis C. Gastroenterology. 103:1992;1285-1289.
17. Quiroga J.A., Martin J., Pardo M., Carreño V. Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon alpha. Dig. Dis. Sci. 39:1994;2485-2496.
18. Kondo M., Tanaka K., Ikeda M., Arata S., Saito S., Sakaguchi T., Morimoto M., Fujii T., Mitsui K., Okazaki H., Hoshino M., Sekihara H. Hepatic HCV-RNA as a predictor of outcome after interferon treatment in patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 11:1996;236-240.
19. Stanley A.J., Haydon G.H., Piris J., Jarvis L.M., Hayes P.C. Assessment of liver histology in patients with hepatitis C and normal transaminase levels. Eur. J. Gastroenterol. Hepatol. 8:1996;869-872.
20. Richard M.J., Guiraud P., Meo J., Favier A. High performance liquid chromatography separation of malondialdehyde thiobarbituric acid adduct in biological materials (plasma and human cell) using a commercially available reagent. J. Chromatogr. 577:1992;9-18.
21. Barbaro G., Di-Lorenzo G., Soldini M., Parrotto S., Bellomo G., Belloni G., Grisorio B., Barbarini G. Hepatic glutathione deficiency in chronic hepatitis C quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease . Am. J. Gastroenterol. 91:1996;2569-2573.
22. Inchauspe G. Protection and defense mechanisms in HCV infection. Nephrol. Dial. Transplant. 11:1996;6-8.
23. Liang C.M., Lee N., Cattell D., Liang S.M. Glutathione regulates interleukin-2 activity in cytotoxic T-cells. J. Biol. Chem. 264:1989;13519-13523.
24. Garewal H.S., Ampel N.M., Watson R.R., Prabhala R.H., Dols C.L. A preliminary trial of beta-carotene in subjects infected with the human immunodeficiency virus. J. Nutr. 122:1992;728-732.
25. Staal F.J.T., Roederer M., Israelski D.M., Bubp J., Mole L.A., McShane D., Deresinski S.C., Ross W., Jussman H., Raju P.A. Intracellular glutathione levels in T cell subsets decrease in HIV infected individuals. AIDS Res. Hum. Retrovir. 8:1992;305-311.
26. Sönnerborg A., Carlin G., Akerlund B., Jarstrand C. Increased production of malondialdehyde in patients with HIV infection. Scand. J. Infect. Dis. 20:1988;287-290.
27. Jareño E.J., Bosch-Morell F., Fernández-Delgado R., Donat J., Romero F.J. Serum malondialdehyde in HIV seropositive children. Free Radic. Biol. Med. 24:1998;503-506.